The American Journal of Surgery
Volume 186, Issue 4 , Pages 362-367, October 2003

Low-risk palpable breast masses removed using a vacuum-assisted hand-held device

Presented at the Fourth Annual Meeting of the American Society of Breast Surgeons, Atlanta, Georgia, April 30–May 4, 2003

  • Richard E Fine, M.D.

      Affiliations

    • The Breast Center, Marietta, GA, USA
  • ,
  • Pat W Whitworth, M.D.

      Affiliations

    • Nashville Breast Center, Nashville, TN, USA
  • ,
  • Julian A Kim, M.D.

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, OH, USA
  • ,
  • Jay K Harness, M.D.

      Affiliations

    • University of California San Francisco-East Bay, Oakland, CA, USA
  • ,
  • Beth A Boyd, R.N.

      Affiliations

    • The Breast Center, Marietta, GA, USA
  • ,
  • William E Burak Jr., M.D.

      Affiliations

    • Ohio State University, 907 N. Doan Hall, 410 West 10th Ave., Columbus, OH 43210, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-614-293-7743; fax: +1-614-293-3465.

Received 3 June 2003; received in revised form 21 June 2003

Abstract 

Background

This study evaluates the safety, efficacy, and patient acceptance of a vacuum-assisted, hand-held biopsy device (Mammatome) in the percutaneous removal of breast masses using ultrasound guidance.

Methods

A multicenter, nonrandomized study evaluated 216 women with low-risk palpable lesions. Lesions 1.5 to 3.0 cm in size were removed using an 8-gauge probe. Those lesions <1.5 cm were removed with the 11-gauge probe. Follow-up evaluation was performed at 10 days and 6 months after biopsy.

Results

A total of 127 patients had biopsies using the 8-gauge probe, and 89 patients had biopsies using the 11-gauge probe. At 6-month follow-up, 98% of the lesions remained nonpalpable, 73% with no ultrasonographically visible evidence of the original lesion. Most complications were mild and anticipated. Most patients (98%) were satisfied with incision appearance, and 92% of patients would recommend the procedure to others.

Conclusions

Percutaneous removal of palpable benign breast masses using the Mammotome system is feasible and safe, and yields high patient satisfaction. The results at 6 months after biopsy demonstrated the effectiveness of benign lesion removal, with correlative clinical data demonstrating lack of palpability and no need for additional procedures. Continuing evaluation of long-term efficacy is ongoing.

Keywords:  Benign breast lesion, Fibroadenoma, Breast biopsy, Mammotome

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-9610(03)00263-0

doi:10.1016/S0002-9610(03)00263-0

The American Journal of Surgery
Volume 186, Issue 4 , Pages 362-367, October 2003